Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Fortrea To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Fortrea between July 3, 2023 and February 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Faruqi & ...

Core Viewpoint - Fortrea has adopted a limited-duration stockholder rights plan to protect the long-term value for all stockholders and ensure fair treatment in potential takeover situations [1][2][3] Summary by Sections Rights Plan Purpose - The Rights Plan aims to enable stockholders to realize long-term investment value and ensure fair treatment during any proposed takeover [2] - It is designed to prevent tactics that could allow control of the Company without appropriate compensation to all stockholders [2] - The plan was initiated in response to significant dislocation in the trading price of the Company's stock and interest from third parties to capitalize on this dislocation [2] Rights Plan Details - The Rights Plan applies equally to all current and future stockholders and does not deter offers or preclude the Board from considering beneficial transactions [3] - Fortrea will issue one right for each share of common stock as of June 23, 2025, with rights becoming exercisable if any person acquires 10% or more of the outstanding common stock [4] - If exercisable, rights holders (excluding the triggering person) can acquire shares at a 50% discount or exchange rights for one share of common stock [4] - The Board can redeem the rights at $0.001 per right, and the plan does not limit future Boards' ability to redeem the rights [4] Company Overview - Fortrea is a leading global provider of clinical development solutions to the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies [6] - The Company offers phase I-IV clinical trial management, clinical pharmacology, and consulting services, leveraging over 30 years of experience across more than 20 therapeutic areas [6]

Thakral succeeds Interim CEO, Peter M. Neupert, who will remain chairman of the board DURHAM, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that Fortrea’s Board of Directors (the “Board”) named Anshul Thakral as Fortrea’s CEO, effective August 4, 2025. He was also appointed to serve as a director on the Company’s Board, effective as of that date. Thakral succeeds Interim CEO, Peter M. Neupert, who will r ...

Group 1 - The high-yield credit market has largely recovered from the correction experienced in early spring [1] - Junk bond funds (HYG) and (JNK) are now approximately flat on the year [1] - The BBB credit spread has shown signs of stabilization following the market correction [1]

10 June 2025 | 11:20AM EDT US Economics Analyst Examining the Impact of High-Skilled Immigrants on the US Economy (Rindels) Jan Hatzius +1(212)902-0394 | jan.hatzius@gs.com Goldman Sachs & Co. LLC Alec Phillips +1(202)637-3746 | alec.phillips@gs.com Goldman Sachs & Co. LLC David Mericle +1(212)357-2619 | david.mericle@gs.com Goldman Sachs & Co. LLC Ronnie Walker +1(917)343-4543 | ronnie.walker@gs.com Goldman Sachs & Co. LLC Manuel Abecasis +1(212)902-8357 | manuel.abecasis@gs.com Goldman Sachs & Co. LLC Els ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Fortrea To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securites in Fortrea between July 3, 2023 and February 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 10, 2025 /PRNewswire/ -- Faruqi & Faruqi, ...

Newly 60 Million USD equivalent investment supports new operating model, accelerates platform unification, and bolsters U.S. and global market ambitionsNEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Cint, the global leader in research and measurement technology, announced the successful completion of a SEK 596 million (~USD 60 million) rights issue, following an oversubscribed offering to existing shareholders. This new capital supports Cint’s multi-phase strategic transformation plan and fuels continued growt ...

Fortrea is a global contract research organization that provides biopharmaceutical product and medical device development solutions. In June 2023, Fortrea was spun off into a standalone, publicly traded company by Labcorp Holdings Inc. ("Labcorp"). In connection with the spin-off, Fortrea entered into several transition services agreements (the "TSAs"), pursuant to which it agreed to pay Labcorp for certain transitional services over a set period. As alleged, Fortrea discussed the significant cost savings a ...

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE). Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/fortrea-holdings-inc-loss-submission-form/?id=151931&from=3 CLASS PERIOD: Ju ...

SAN DIEGO, June 9, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fortrea Holdings Inc. (NASDAQ: FTRE) securities between July 3, 2023 and February 28, 2025, both dates inclusive (the "Class Period"), have until August 1, 2025 to seek appointment as lead plaintiff of the Fortrea class action lawsuit.  Captioned Deslande v. Fortrea Holdings Inc., No. 25-cv-04630 (S.D.N.Y.), the Fortrea class action lawsuit charges Fortrea and certain of Fortrea's top executive ...